Rucci Carolyn M. 4

4 · Akebia Therapeutics, Inc. · Filed Feb 3, 2026

AI-generated summary of this filing

Updated Feb 3, 2026

Akebia (AKBA) SVP Carolyn Rucci Receives RSUs & Stock Options

What Happened

Carolyn M. Rucci, Senior Vice President and Chief Legal Officer of Akebia Therapeutics (AKBA), received two equity awards on January 30, 2026: 190,000 restricted stock units (RSUs) and 270,000 stock options. Both awards were granted at no cash cost to the reporting person (reported acquisition price $0.00), reflecting standard equity compensation rather than an open-market purchase or sale.

Key Details

Transaction date: 2026-01-30; Form 4 filed: 2026-02-03 (filed within the two-business-day SEC deadline).
RSUs: 190,000 shares granted under the Issuer’s 2023 Stock Incentive Plan (footnote F1). Vesting: one‑third on each of the first, second and third anniversaries of the grant date, subject to continued service.
Options (derivative): 270,000 options granted under the 2023 Stock Incentive Plan (footnote F2). Vesting: 25% on the first anniversary, remainder vesting in equal quarterly installments over the following three years, subject to continued service.
Reported acquisition price for both awards: $0.00 (typical for grants). The filing does not disclose the number of shares owned by Ms. Rucci after these grants in the information provided here.
Transaction code: A = Award/Grant; derivative indicates stock options. No 10b5-1 plan, tax withholding, or late filing noted in the filing excerpt provided.

Context

These are compensatory grants, not purchases or sales; they are intended as employee compensation and vest over time, so they do not represent immediate realizable cash value unless/ until vested and exercised/sold.
For options, vesting and any exercise price (if applicable) determine future value and timing; the filing shows these as option grants (derivative awards) but does not show an exercise price or intrinsic value in this summary.

Form 4

Period: 2026-01-30

SVP, Chief Legal Officer

Transactions

Award
Common Stock
[F1]
2026-01-30+190,000→ 658,150 total
Award
Stock Option (Right to buy)
[F2]
2026-01-30+270,000→ 270,000 total
Exercise: $1.41Exp: 2036-01-30→ Common Stock (270,000 underlying)

Footnotes (2)

[F1]The restricted stock units were granted by the Issuer pursuant to its 2023 Stock Incentive Plan, as amended. One third of the restricted stock units will vest on each of the first, second and third anniversaries of the grant date, subject to the reporting person's continued service with the Issuer on each vesting date.
[F2]The options were granted by the Issuer pursuant to its 2023 Stock Incentive Plan, as amended. The options will vest over four years: 25% of the options will vest on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter, subject to the reporting person's continued service with the Issuer on each vesting date.

Signature

/s/ Carolyn M. Rucci|2026-02-03

1 file